arrow
E

Emanuele Vita

university of parma
H指数:14
被引数:844

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study

根据KRAS状态评估一线化疗联合免疫疗法在晚期非鳞状NSCLC中的疗效:一项意大利真实世界研究

2026-08-010
PRE
Corrigendum to “Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed” [Eur J Cancer 202, May 2024, 114006]

对“意大利接受一线帕博利珠单抗联合铂类/培美曲塞治疗的晚期非鳞状细胞肺癌患者的真实世界结局”的勘误 [Eur J Cancer 202, 2024年5月, 114006]

2026-06-270
PRE
Primary adrenal insufficiency induced by immune checkpoint inhibitors (ICIs): a case series and systematic literature review

免疫检查点抑制剂(ICIs)诱导的原发性肾上腺功能不全:病例系列和系统文献综述

2026-05-300
OAAI
PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance

PI3K/mTORC2-RICTOR轴在早期鳞状非小细胞肺癌中的研究:基因组学、分子表达及其临床相关性

2025-11-070
OA
Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib

NRG1变异体不确定意义(VUSes)在晚期非小细胞肺癌中的网络分析及其在EGFR突变患者接受一线奥希替尼治疗中的预后作用

2025-08-290
OAAI
Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis

化疗免疫治疗后的小细胞肺癌的巩固性胸放射治疗:一项多中心回顾性分析

2025-06-250
PRE
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study
2024-10-220
OA
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
2024-05-013
PRE
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research
2024-03-011
OAAI
Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study (vol 23, 540, 2023)
2023-11-090
OAAI
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results
2023-07-016
PRE
Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study

肺癌多组学数字人体化身将精准医学融入临床实践: 灯笼研究

2023-06-1313
OAAI
Clinical Stage III NSCLC Patients Treated with Neoadjuvant Therapy and Surgery: The Prognostic Role of Nodal Characteristics

接受新辅助治疗和手术治疗的临床III期NSCLC患者: 淋巴结特征的预后作用

2022-11-014
OAAI
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer

解开有丝分裂纺锤体: 肺癌中的极光激酶抑制剂的重点

2022-10-279
OAAI